Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A11778
Buy Now

Market Overview:

The 7 major metastatic HER2-positive breast cancer markets are expected to exhibit a CAGR of 1.18% during 2024-2034.

Report Attribute
Key Statistics
Base Year 
2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Growth Rate 2024-2034 1.18%


The metastatic HER2-positive breast cancer market has been comprehensively analyzed in IMARC's new report titled "Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Metastatic HER2 (human epidermal growth factor receptor 2)-positive breast cancer is an advanced stage of breast cancer characterized by the presence of HER2 protein overexpression. It tends to be more aggressive than other forms of cancer due to its accelerated growth and increased likelihood of spreading beyond the breast tissue. The symptoms of this illness may include a palpable lump in the breast or underarm, alterations in breast shape or size, skin dimpling, nipple changes, persistent pain, and bone fractures. As the cancer advances, it can spread to distant organs, such as the brain, bones, lungs, or liver, causing further complications. The diagnosis of metastatic HER2-positive breast cancer typically requires a combination of clinical findings and physical investigations. The healthcare provider will also perform numerous diagnostic procedures, including a mammogram or ultrasound, a biopsy of the tumor tissue to confirm HER2 positivity, and imaging studies to determine the extent of metastasis.

Metastatic HER2-Positive Breast Cancer Market

The increasing incidences of genetic variations in the BRCA1 and BRCA2 genes, resulting in uncontrolled growth and division of abnormal cells that originate in the breast tissue, are primarily driving the metastatic HER2-positive breast cancer market. In addition to this, the inflating utilization of innovative approaches, such as antibody-drug conjugates and immune checkpoint inhibitors, which help in harnessing the body's immune response to combat cancerous cells, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive therapies, including immunotherapies, bisphosphonates, and pain management strategies, aimed at enhancing patients' overall well-being and mitigating treatment-related complications, is further bolstering the market growth. Apart from this, the rising usage of precision medicine approaches, since they involve tailoring treatments based on the genetic makeup of the tumor, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive procedures, such as radiofrequency ablation and cryoablation to precisely target and eliminate tumor masses in individuals suffering from the illness is also augmenting the market growth. Furthermore, the escalating application of gene-targeting treatments that aim to correct or inhibit the overexpression of the HER2 gene is expected to drive the metastatic HER2-positive breast cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the metastatic HER2-positive breast cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for metastatic HER2-positive breast cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the metastatic HER2-positive breast cancer market in any manner.

Time Period of the Study

  •  Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034


Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the metastatic HER2-positive breast cancer market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the metastatic HER2-positive breast cancer market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current metastatic HER2-positive breast cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance    
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Perjeta (Pertuzumab) Genentech
Tukysa (Tucatinib) Seagen
Nerlynx (Neratinib) Puma Biotechnology
Margenzatm (Margetuximab-Cmkb) MacroGenics
Enhertu (Fam-Trastuzumab Deruxtecan-Nxki) Daiichi Sankyo
Pertuzumab Genentech
Inavolisib Roche Pharma
Giredestrant Roche Pharma
ZN-A-1041 Suzhou Zanrong Pharm
Palbociclib Pfizer


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the metastatic HER2-positive breast cancer market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the metastatic HER2-positive breast cancer market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the metastatic HER2-positive breast cancer market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (​2018-2034​) of metastatic HER2-positive breast cancer across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of metastatic HER2-positive breast cancer by age across the seven major markets?
  • What is the number of prevalent cases (​2018-2034​) of metastatic HER2-positive breast cancer by gender across the seven major markets?
  • How many patients are diagnosed (​2018-2034​) with metastatic HER2-positive breast cancer across the seven major markets?
  • What is the size of the metastatic HER2-positive breast cancer patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of metastatic HER2-positive breast cancer?
  • What will be the growth rate of patients across the seven major markets?
     

Metastatic HER2-Positive Breast Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for metastatic HER2-positive breast cancer drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the metastatic HER2-positive breast cancer market?
  • What are the key regulatory events related to the metastatic HER2-positive breast cancer market?
  • What is the structure of clinical trial landscape by status related to the metastatic HER2-positive breast cancer market?
  • What is the structure of clinical trial landscape by phase related to the metastatic HER2-positive breast cancer market?
  • What is the structure of clinical trial landscape by route of administration related to the metastatic HER2-positive breast cancer market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Metastatic HER2-Positive Breast Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More